DA-JC4

CAT:
804-HY-P3255-01
Size:
1 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
DA-JC4 - image 1

DA-JC4

  • UNSPSC Description:

    DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways[1][2][3].
  • Target Antigen:

    Insulin Receptor
  • Type:

    Peptides
  • Related Pathways:

    Protein Tyrosine Kinase/RTK
  • Applications:

    COVID-19-immunoregulation
  • Field of Research:

    Inflammation/Immunology; Neurological Disease
  • Assay Protocol:

    https://www.medchemexpress.com/da-jc4.html
  • Solubility:

    10 mM in DMSO
  • Smiles:

    O=C([C@@H](NC(C(C)(NC([C@H](CC1=CC=C(C=C1)O)N)=O)C)=O)CCC(O)=O)NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NC(C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N2[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N3[C@H](C(N4[C@H](C(N5[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)CCCCN)=O)CCCCN)=O)CCCCN)=O)CCCCN)=O)CCCCN)=O)CCCCN)=O)CO)=O)CCC5)=O)CCC4)=O)CCC3)=O)C)=O)=O)CO)=O)CO)=O)CCC2)=O)=O)=O)C)=O)CC(C)C)=O)CC(C)C)=O)CC6=CNC7=CC=CC=C67)=O)CC(N)=O)=O)C(C)C)=O)CC8=CC=CC=C8)=O)CCC(O)=O)=O)(C)C)=O)C)=O)C)=O)CCC(N)=O)=O)CCCCN)=O)CC(O)=O)=O)CC(C)C)=O)CC9=CC=C(O)C=C9)=O)[C@H](CC)C)=O)CO)=O)CC%10=CC=C(O)C=C%10)=O)CC(O)=O)=O)CO)=O)[C@@H](C)O)=O)CC%11=CC=CC=C%11)=O)[C@@H](C)O)=O
  • Molecular Weight:

    4875.49
  • References & Citations:

    [1]Shi L, et al. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model. Behav Brain Res. 2017;327:65-74.|[2]Feng P, et al. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease. Neuropharmacology. 2018;133:385-394.|[3]Li T, et al. Neuroprotection of GLP-1/GIP receptor agonist via inhibition of mitochondrial stress by AKT/JNK pathway in a Parkinson's disease model. Life Sci. 2020;256:117824.
  • Shipping Conditions:

    Blue Ice
  • Storage Conditions:

    -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)
  • Clinical Information:

    No Development Reported
  • CAS Number:

    2315504-40-4